Skip to main content

NOW APPROVED

First and only FDA-approved Biologic for APPROPRIATE patients with CSU as young as 2 years of age who remain symptomatic despite H1 antihistamine treatment

Not an actual patient.

REDUCTION IN ITCH AND HIVES
IN BIOLOGIC-NAIVEa PATIENTS1,2

Clinical trial results in patients 12+ years of age

Iss7

Reduction in weekly itch
severity score at Week 24

EXPLORE ITCH EFFICACY

Hss7

Reduction in weekly hives
severity score at Week 24

EXAMINE HIVES EFFICACY

UAS7 (ISS7+HSS7)

Reduction in disease activity
at Week 24, with some patients even reporting complete response

EVALUATE OUTCOMES
  • aBiologic-naive defined as no anti-IgE treatment.
  • Use of DUPIXENT for the CSU indication in patients aged 2-11 years is supported by evidence from two studies of DUPIXENT in CSU patients 12+ years of age.1

Demonstrated safety profile in csu1

Most common adverse reactions
(incidence ≥2%) in patients 12+ years of age with chronic spontaneous urticaria are
injection site reactions.b

The safety of DUPIXENT was assessed in 18 subjects 2-11 years of age who received DUPIXENT based on weight.
No new adverse reactions were identified in pediatric subjects aged 2-11 years who received DUPIXENT.1

  • bInjection site reactions cluster includes injection site dermatitis, injection site erythema, injection site hematoma, injection site induration, injection site pain, injection site pruritus, injection site reaction, injection site swelling.

Explore safety profile

the only dual inhibitor of il-4
and il-13 signaling

The mechanism of dupilumab action
has not been definitively established.

See how it works

Attributes And Considerations

NOT AN
IMMUNOSUPPRESSANT
OR
A STEROID1

NO INITIAL LAB TESTING
OR
ONGOING LAB
MONITORING

according to the
Prescribing Information1

NO KNOWN DRUG‑TO‑DRUG
INTERACTIONS1

  • Not metabolized through
    the liver or
    excreted
    through the kidneys

At-home
self-
administration1

  • Train patients and/or
    caregivers on
    proper
    administration prior to use

NO boxed warning1

Please see additional
Warnings and Precautions
in the Prescribing
Information and Important
Safety Information below.

Select important safety information

WARNINGS AND PRECAUTIONS

  • Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum
    sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP
    was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction
    occurs, institute appropriate therapy and discontinue DUPIXENT.

More than 1 million patients

On Therapy Across
Approved
indications
Worldwide2,c

  • dThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through February 2026.
  • AD, atopic dermatitis; BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; EoE, eosinophilic esophagitis; HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; PN, prurigo nodularis; UAS7, urticaria activity score over 7 days.

Discover who may be appropriate for DUPIXENT

See profiles of potential CSU patients you might see in your practice.

Identify Patients
Dupixent MyWay® Logo

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

Discover DUPIXENT MyWay Program benefits

DUPIXENT MyWay
ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form